Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.

COVID-19, other infections linked to major cardiovascular risks—researchers push for vaccination
Adults are three times as likely to have a heart attack or stroke after a COVID-19 infection than when they are healthy. The risks are even greater for the flu.
Novo Nordisk, Pfizer enter bidding war for biotech startup—and it is getting ugly
Pfizer was all set to acquire New York City-based Metsera for $4.9 billion, but Novo Nordisk stepped in with an unexpected counteroffer of $6.5 billion. Both companies hope to add Metsera's drugs to their GLP-1 portfolios.
Nearly 600K bottles of blood pressure drug recalled due to carcinogen risk
The FDA has detailed three voluntary recalls for prazosin hydrochloride, a medication used to treat hypertension, due to safety concerns.
Clinical trials paused due to heart patient’s hospitalization
Intellia Therapeutics paused clinical trials for ATTR-CM and ATTR-PN after a patient was hospitalized due to a significant liver injury.
New drug recall includes more than 140K bottles of popular statin
According to the FDA, the drugs are not dissolving correctly. This can impact their ability to lower a patient’s cholesterol as intended.

Empagliflozin may reverse vascular aging, lower CVD risk

The SGLT2 inhibitor is already known as an effective medication for both type 2 diabetes and heart failure.

Anagrelide capsules FDA recall Teva Pharmaceuticals USA

FDA announces recall of platelet-reducing medication due to risk of clotting or other adverse cardiovascular outcomes

The medication failed a routine dissolution test, meaning it could lose its effectiveness.

FDA posts guidance on managing risk of drug shortages

The Food & Drug Administration has drafted guidelines to help U.S. healthcare better prepare for and respond to events associated with these situations.

The FDFA has cleared tirzepatide (Mounjaro) from Eli Lilly for the treatment of diabetes.

FDA approves tirzepatide, Eli Lilly’s new type 2 diabetes drug, and the company shares an estimated price

The medication, sold under the name Mounjaro, will be available in six different doses and come in an auto-injector pen.

FDA asks drug makers to address shortages

Drug shortages have been impacted by COVID-19, with 95% of doctors believing the pandemic exposed weaknesses in the medicine supply chain.

New bleeding stroke guidelines highlight several common treatments that may be ineffective

The updated document, developed by the American Heart Association and American Stroke Association, also emphasizes the potential benefits of caregiver training and MR imaging.

Flu shots lower CVD risk, new meta-analysis confirms

The study's authors tracked data from six different randomized controlled trials, including a large study from 2021 that focused on myocardial infarction patients.

Combining certain BP medications with NSAIDs linked to kidney damage—acetaminophen seen as a safer option

A team of researchers used computer science and mathematics to study the "triple whammy" of diuretics, RAS inhibitors and NSAIDs.

Pharmaceutics

COVID-19, other infections linked to major cardiovascular risks—researchers push for vaccination

Novo Nordisk, Pfizer enter bidding war for biotech startup—and it is getting ugly

Nearly 600K bottles of blood pressure drug recalled due to carcinogen risk

Clinical trials paused due to heart patient’s hospitalization

New drug recall includes more than 140K bottles of popular statin